Carnexiv Patent Expiration

CARNEXIV's oppositions filed in EPO
CARNEXIV IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770407 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation
Nov, 2028

(4 years from now)

US9629797 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation
Nov, 2028

(4 years from now)

US9750822 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US7635773 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US8410077 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9493582 LUNDBECK PHARMS LLC Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)

US11529357 LUNDBECK PHARMS LLC Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
Jan, 2040

(15 years from now)



Carnexiv is a drug owned by Lundbeck Pharmaceuticals Llc. It is used for treating mixed seizure patterns in adults. Carnexiv uses Carbamazepine as an active ingredient. Carnexiv was launched by Lundbeck Pharms Llc in 2016. It is is available in solution form for intravenous use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 31, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 07, 2023
Orphan Drug Exclusivity(ODE-124) Oct 07, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: Replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or gener...

Dosage: SOLUTION

More Information on Dosage

CARNEXIV family patents

Family Patents